Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis–A systematic review and network meta-analysis
- 15 January 2021
- journal article
- review article
- Published by Elsevier BV in Multiple Sclerosis and Related Disorders
- Vol. 49, 102769
- https://doi.org/10.1016/j.msard.2021.102769
Abstract
No abstract availableKeywords
Funding Information
- Merck
- Merck KGaA
This publication has 35 references indexed in Scilit:
- Modelling the Dynamics of an Experimental Host-Pathogen Microcosm within a Hierarchical Bayesian FrameworkPLOS ONE, 2013
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2012
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2011
- CladribineClinical Neuropharmacology, 2011
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisThe New England Journal of Medicine, 2010
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”Annals of Neurology, 2005
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Rating neurologic impairment in multiple sclerosisNeurology, 1983